Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter (“OTC”) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.
In the company’s own words · 10-K filed May 14, 2026 · SEC EDGAR
Business segments
Jun 2026 · $231.6MThe company’s own SEC segment disclosure.
- Womens Health$47.2M20%
- Gastrointestinal$47.1M20%
- Dermatologicals$30.6M13%
- Eye And Ear Care$28.3M12%
- Pain Relief$26.2M11%
- Oral Care$18.5M8%
- Other (3)$33.6M14%
Prestige Consumer Healthcare Inc. (PBH) reported revenue of $282M in Q4 2026 (quarter ended Mar 31, 2026), down 5.0% from the same quarter a year earlier. That came with a gross margin of 52% and net income of $54M (19% of revenue). For the full year FY2026, revenue was $1.09B (−4.3% year on year) and net income $190M. Its largest product in Jun 2026 was Womens Health at $47M, 20.4% of the disclosed total, just ahead of Gastrointestinal at 20.4%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #23 of 29 by Smart Score